Approval · Notice of Compliance 5119 · 1995
MEVACOR: Notice of Compliance 5119
Issued March 15, 1995
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 5119
- Date
- March 15, 1995
- Company
- Merck Frosst Canada Inc.Kirkland, QC, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: for use to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL-cholesterol to target levels
- Therapeutic class
- Lipid metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MEVACOR | Not yet assigned | — |
Medicinal ingredients
- LOVASTATIN 10 MG per TAB
- LOVASTATIN 20 MG per TAB
- LOVASTATIN 40 MG per TAB